| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 9.21 | 61.52 | -8.88 | -6.9 |
Op profit growth | 15.5 | 31.74 | 3.4 | -22.17 |
EBIT growth | -3.25 | 170.16 | 78.77 | -38 |
Net profit growth | -34.06 | -717.69 | -67.42 | 79.68 |
Profitability ratios (%) | ||||
OPM | 10.37 | 9.81 | 12.02 | 10.59 |
EBIT margin | 6.16 | 6.95 | 4.15 | 2.11 |
Net profit margin | 6.8 | 11.26 | -2.94 | -8.24 |
RoCE | 7.59 | 7.5 | 2.26 | 1.12 |
RoNW | 2.42 | 4.26 | -0.72 | -2.04 |
RoA | 2.09 | 3.03 | -0.4 | -1.09 |
Per share ratios (₹) | ||||
EPS | 30.47 | 50.04 | -8.1 | 0 |
Dividend per share | 0 | 0 | 0 | 0 |
Cash EPS | 5.37 | 21.46 | -34.03 | -52.28 |
Book value per share | 329.5 | 324.32 | 262 | 293.23 |
Valuation ratios | ||||
P/E | 8.82 | 5.48 | -2.77 | 0 |
P/CEPS | 49.97 | 12.79 | -0.66 | -1.25 |
P/B | 0.81 | 0.84 | 0.08 | 0.22 |
EV/EBIDTA | 4.99 | 4.88 | 5.33 | 9.2 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 0 |
Tax payout | 11.85 | 52.61 | -252.87 | 11.47 |
Liquidity ratios | ||||
Debtor days | 21.53 | 20.88 | 41.92 | 46.33 |
Inventory days | 74.88 | 86.93 | 150.2 | 136.61 |
Creditor days | -41.73 | -40.2 | -40.81 | -32.88 |
Leverage ratios | ||||
Interest coverage | -76.69 | -2.92 | -1.05 | -0.22 |
Net debt / equity | -0.01 | 0.04 | 0.67 | 0.83 |
Net debt / op. profit | -0.12 | 0.37 | 5.34 | 7.67 |
Cost breakup (₹) | ||||
Material costs | -64.38 | -62.17 | -51.36 | -55.06 |
Employee costs | -8.74 | -8.39 | -13.56 | -10.55 |
Other costs | -16.49 | -19.61 | -23.04 | -23.77 |
The Unit-II Baddi plant, which got the renewed certification, has state-of-art infrastructure and state-of-the-art manufacturing technology to cater to complex therapeutic segments in an efficient manner.
The company is now set to further expand into Eastern Europe as this recognition ensures patients and healthcare providers have access to reliable and effective antibiotics.
Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
